



IMCLGS Overview

***Janet A. Warrington, Ph.D.
Vice President
Molecular Diagnostics
Research and Development
Affymetrix Inc.***



International Meeting on Clinical and Laboratory Genomic Standards

May 2005, Paris

- 40 participants
- 14 countries
 - UK, Sweden, Belgium, Germany, Scotland, Ireland, France, Spain, Japan, Australia, China, USA, Singapore, Canada
- 13 agencies
 - SFDA, FDA, LGC, IFCC, CLSI, OECD, NIST, NIAID, EC, EORTC, BIPM/IRMM, CDC, IPTS
- 13 universities/medical centers
 - Our Lady's Hospital, Karolinska, Institut Curie, Texas Medical Center, Australian Genome Research Facility, Univ. Tokyo, Kyoto U, Uppsala U, GIS, Quebec Univ, U Leuven, Univ Muenchen, National Genetics Reference Lab UK
- 9 companies
 - Affymetrix, Ambion, Qiagen, Expression Analysis, Roche, BMX, CapitalBio, MLNM, Tetracore



Goals

- Accelerate the establishment of clinical and laboratory genomic standard controls
- Identify areas in which global harmonization in the development and application of standard controls and guidelines are possible
- Increase stakeholder interaction
 - Open
 - Volunteer effort
 - www.imclgs.net
 - Conference calls, quarterly



Current activities

- Pursuing the development of recommendations for selection criteria and characterization of DNA controls for evaluating technical performance, their associated metrics and the information reported
- Determining actions to facilitate harmonizing data standards initiatives including algorithm selection criteria, reporting issues and database standardization



Information

- www.imclgs.net
- janet_warrington@affymetrix.com



**Prioritization of Needs:
Recommendations for selection criteria and
characterization of DNA controls
Discussion**



Discussion

Recommendations for selection criteria and characterization of DNA controls for evaluating technical performance, their associated metrics and the information reported

- Reference Material
 - **Fit for purpose**
 - **Independently confirmed**
 - **Stabile**
 - **Homogeneous**
 - **Renewable, accessible**
 - **Traceable**
 - **Super/meta/synthetic vs. biological source**
 - **Complexity (re: similarity to sample)**
 - **Concentration**
 - **Purity**



Discussion

Recommendations for selection criteria and characterization of DNA controls for evaluating technical performance, their associated metrics and the information reported

- Metrics
 - Ratio/s
 - Absolute values
 - Threshold/s